According to the China Medical Device Innovation and Priority Approval Database, two innovative medical devices have entered the special review process in recent public announcements released by local drug regulatory authorities across the country. They are respectively the exercise rehabilitation system of Beijing Tianxing Medical Co., Ltd. (hereinafter referred to as Tianxing Medical) and the disposable angle guided puncture needle of Jiangsu Chunzhen Medical Technology Co., Ltd. (hereinafter referred to as Chunzhen Medical).

Tianxing Medical, a leading domestic enterprise in sports medicine
Tianxing Medical was founded in 2017 and is a leading domestic enterprise in sports medicine, committed to providing comprehensive clinical solutions for sports medicine. Its products are used in sports medicine equipment, implants, and surgical instruments for shoulder joints, knee joints, foot/ankle joints, hip joints, elbow joints, and hand/wrist joints, with a total of more than 300 specifications approved by NMPA. They have been clinically applied in thousands of hospitals in 31 provinces, municipalities, and autonomous regions in China.

At present, Tianxing Medical has established three major product segments: sports medicine implants, active devices and consumables, and surgical tools, and has conducted systematic research and development and layout around emerging fields such as sports medicine smart healthcare and regenerative sports medicine.

In the field of implants, a variety of implant products have been launched, including polyetheretherketone materials, absorbable materials, and full suture materials. Among them, 11 products are the first domestically approved products, full suture anchors are the first domestically approved and clinically applied products, and the full suture meniscus suture system is the first domestically produced full suture meniscus product;

In the field of active equipment and consumables, Tianxing Medical provides comprehensive support for arthroscopic equipment and consumables in sports medicine surgery, including endoscopic camera systems, endoscopic surgical planers, plasma surgical equipment, and disposable planers, electrodes, and other consumables used in conjunction with them.

Tianxing Medical has broken through many major key technologies in sports medicine products, such as injection molding, weaving, preparation and processing of absorbable materials, and development of active devices. It has established two core technology platforms: sports medicine implant development platform and imaging power energy platform, becoming a domestic enterprise that can provide overall clinical solutions for sports medicine.

At the end of 2023, Tianxing Medical submitted its IPO prospectus and plans to go public on the Science and Technology Innovation Board. On December 31, 2024, Tianxing Medical updated and submitted relevant financial information, and resumed auditing. According to the latest prospectus, starting from 2021, Tianxing Medical's revenue has been on a continuous upward trend. From January to September 2021, 2022, 2023, and 2024, Tianxing Medical's revenue was RMB 73.01 million, RMB 148 million, RMB 241 million, and RMB 223 million respectively, and its net profit also showed a good growth trend: negative RMB 110 million, RMB 40.34 million, RMB 63.58 million, and RMB 64.08 million.

Chunjun Medical specializes in the field of tumor intervention
Chunyun Medical was established in 2021 and is a subsidiary of Jiangsu Kangsheng Digital Medical Technology Co., Ltd. (hereinafter referred to as Jiangsu Kangsheng). The company has an intelligent puncture navigation system, a recyclable pulmonary nodule puncture positioning balloon and needle, a voice controlled knee replacement surgical stent, and the remaining 17 are utility model patents.

Jiangsu Kangsheng was established in 2019, with drug agency sales as its core, gradually forming a company that integrates research, production, and sales. At present, it is divided into two major sections. The Pharmaceutical Division mainly focuses on drug agency, direct sales, and clinical academic promotion; The Tumor Intervention Device Division is a physical company that integrates research and development with production, committed to becoming a respected leader in the field of tumor intervention in China.

At present, the global incidence rate of cancer continues to grow, and the number of cancer deaths continues to soar. According to IARC data, the total number of global cancer cases is expected to increase to 35.3 million by 2050, a 76.6% increase from the estimated 20 million in 2022. The global cancer death toll is expected to reach 18.5 million by 2050, an increase of 89.7% from the estimated 9.7 million in 2022.

In the treatment of malignant tumors, interventional therapy has become a first-line treatment for some tumors and an indispensable and important component in the current diagnosis and treatment process of malignant tumors. According to their diagnosis and treatment targets, they can be classified as treatments for malignant tumors themselves, treatments for malignant tumor complications, and other auxiliary diagnostic and therapeutic techniques.

Interventional medicine refers to the use of digital subtraction angiography CT、 Under the guidance of medical imaging equipment such as magnetic resonance imaging and ultrasound, the emerging discipline of diagnosing and treating diseased tissues or organs through specialized instruments such as guide wires and catheters has advantages such as minimally invasive, safe, and efficient.

According to publicly available data, the global interventional oncology market is expected to reach a size of $2.02 billion in 2023. The market is expected to grow from $2.18 billion in 2024 and reach $4.04 billion in 2032, with a compound annual growth rate (CAGR) of 8% during the forecast period (2024-2032).

Conclusion
With the support of policies and the promotion of continuous technological development, the "gold content" of domestic medical devices is becoming increasingly high, and local medical devices are continuously shining with new brilliance.

Source: https://news.yaozh.com/archive/44847.html